Ramucirumab
Ramucirumab
Definition
A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.
Also known as Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC 1121B, IMC-1121B, IMC1121B, LY 3009806, LY-3009806, LY3009806, Monoclonal Antibody HGS-ETR2, RAMUCIRUMAB — per NCIT
Also identified as
- ATC L01FG02 per RXNORM
- NCIT NCIT:C70792 per NCIT
- SCTID 704259004 per RXNORM
- SCTID 704260009 per RXNORM
- UNII D99YVK4L0X per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Colorectal neoplasm | may treat | MEDRT · Public domain (U.S. Government work) |
| Gastric neoplasm | may treat | MEDRT · Public domain (U.S. Government work) |
| Non-small cell lung carcinoma | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Lungs | may treat a disease of this organ | DERIVED · CC BY 4.0 |
1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.